Navigating the treatment of renal cell carcinoma: Insights on the current treatment landscape and managing patient health

First Line Medical Treatment of Metastatic Renal Cell Carcinoma: A Podcast on Choosing Wisely and Managing Safely

With recent advancements in medical treatments for metastatic renal cell carcinoma (mRCC), increased treatment efficiency may also come with increased toxicity. In this podcast, authors discuss the appropriate management of the adverse events that result from drug toxicity in order to achieve optimal oncological outcomes for their patients whilst still maintaining their quality of life.

• Read the English-language transcript
• Read the German-language transcript

Ivanyi, P., Wiegmann, J.P., Eggers, H. et al. First Line Medical Treatment of Metastatic Renal Cell Carcinoma: A Podcast on Choosing Wisely and Managing Safely. Adv Ther 40, 3620–3625 (2023). https://doi.org/10.1007/s12325-023-02571-5

A Podcast Discussion on the Current Treatment Landscape for Renal Cell Carcinoma

This podcast covers the recent developments in the treatment of metastatic renal cell carcinoma (mRCC) and the ongoing phase 3 trials in this space. Whilst reflecting on these data, as well as the current ESMO guidelines, authors discuss how to choose the appropriate treatment for individualized treatment journeys for patients and talk through the strengths and weaknesses of first-line therapy options.

• Read the English-language transcript
• Read the German-language transcript

Ivanyi, P., Wiegmann, J.P., Eggers, H. et al. A Podcast Discussion on the Current Treatment Landscape for Renal Cell Carcinoma. Adv Ther 40, 3610–3619 (2023). https://doi.org/10.1007/s12325-023-02569-z

Funding statement

This programme is supported by an unrestricted educational grant from Eisai Europe Limited. Eisai Europe Limited has had no input into the speakers and content.

Disclaimer

Any information provided and opinions expressed do not necessarily reflect the views of Springer Medizin GmbH. Springer Medizin GmbH and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.

Author Contributions

Philipp Ivanyi, Viktor Grünwald, Jonas Paul Wiegmann, and Hendrik Eggers undertook data research on the topic; Philipp Ivanyi drafted the podcast; Philipp Ivanyi and Viktor Grünwald recorded the podcast.